17 hrs ago
Positive Phase III Results Reported for BAX 855 in Treatment of Hemophilia A
Positive results have been reported from a phase III pivotal trial of BAX 855 , an investigational, extended half-life recombinant factor VIII treatment for hemophilia A based on Advate .
Nikolai Strikes Back
GREAT LAKES HEMOPHILIA FOUNDATION FUNDRAISER My great-grandson, Nikolai Jopek, was born with severe type 3 Hemophilia on July 26, 2012.
Thu Aug 21, 2014
Baxter Announces Positive Top-Line Results from Its Phase 3 Study of...
Top-line results from the prospective, global, multi-center Phase 3 study demonstrated that BAX 855 met its primary endpoint in the control and prevention of bleeding, routine prophylaxis and perioperative management for patients who were 12 years or older.
Long-Acting Version Of Baxter International, Inc.'s Hemophilia A Drug BAX 855 Succeeds In Study
Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients * Twice-Weekly Prophylactic Regimen Resulted in 95% Reduction in Median Annualized Bleed Rate Compared to On-Demand * Company Initiating Phase 3 Study of BAX 855 in Pediatric Hemophilia A Patients DEERFIELD, ... (more)
Long-acting version of Baxter's hemophilia drug succeeds in study
Baxter International Inc said a more potent version of its flagship blood disorder drug Advate met the main goal in a late-stage study.
Baxter hemophilia drug successful in Phase 3 trial
In a 138-patient Phase 3 clinical trial evaluating the safety and efficacy of Baxter International's BAX 855 , an extended half-life recombinant factor VIII for the treatment of hemophilia A, the product candidate met its primary endpoint of reducing annualized bleed rates in the prophylaxis arm versus the on-demand arm.
Tue Aug 19, 2014
AIDS Retrospective Pictures Slideshow: A Pictorial Timeline of the HIV/AIDS Pandemic
The first cases of AIDS were reported in 1981, and since then, more than 25 million people worldwide have died from the illness.
Mon Aug 18, 2014
Foundation reviews triumphs, challenges of AIDS fight
In the future, researchers could develop an injection to prevent HIV/a AIDS, and those who have the disease could become so adept at managing it that they might have to visit their doctors only once a year.
Cerebral and Sinus Vein Thrombosis [Cardiology Patient Page]
From the Department of Medicine, Division of Hematology-Oncology, University of North Carolina School of Medicine , and the Hemophilia and Thrombosis Center, University of North Carolina , Chapel Hill, NC.
Expression Therapeutics LLC Selects ABL, Inc. to Support Cell Line...
Expression Therapeutics' recombinant factor VIII platform generates 100-fold greater expression than current products.
Sat Aug 16, 2014
Senator pushes accessible aid for Filipinos with 'Royal Disease'
Philippine Senator Grace Poe flanked by Kalayaan 2014 Asst. Secretary Mary Ann Omega and President Emeritus of the Filipino-American Chamber of Commerce of Los Angeles and past Kalayaan Chair and Chairman of the National Federation of Filipino American Associations Noel S. V. Omega during the senator's arrival at Los Angeles International Airport .
Fri Aug 15, 2014
Regado Biosciences' Revolixys Kit: Assessing The Risks Of Allergic Reactions
Regado Biosciences is currently involved in a phase III clinical trial for Revolixys Kit, its system for precisely controlling blood clotting.
Wed Aug 13, 2014
Alnylam Pharmaceuticals Posts Second Quarter Results
The non-GAAP net loss for the second quarter of 2014 excludes the reduction to in-process research and development expense related to the purchase of the Sirna RNAi assets from Merck.
The Motley Fool
3 Reasons Baxter International Inc.'s Stock Could Rise
You're about to live through that well-known saying, "Crisis equals opportunity."
Tue Aug 12, 2014
Hyperactive PiggyBac Transposons for Sustained and Robust Liver-targeted Gene Therapy
Correspondence: Thierry VandenDriessche, Department of Gene Therapy and Regenerative Medicine, Free University of Brussels, Laarbeeklaan, Brussels, Belgium.
Baxter International: A Spin-Off Play And An Increasing Dividend
Baxter International is a company that is entering an exciting period. After acquiring some businesses and divesting others over recent years, the company has decided to split into two separate companies.
Mon Aug 11, 2014
OPKO Announces Second Quarter Operating and Financial Results
OPKO Health, Inc. , a multi-national biopharmaceutical and diagnostics company, today reported operating and financial results for its second quarter ended June 30, 2014.
Medical Device/Diagnostic Ind.
Which Medtech Companies Hired the Most People in 2013?
Baxter International with headquarters in Deerfield, Illinois, makes products that treat hemophilia, kidney disease, immune disorders and other chronic diseases and conditions.
Baxter Opens Its First Biologics Facility in Asia
Baxter International Inc. announced the formal opening of its first advanced recombinant biologic facility in Singapore and expansion plans for a new recombinant protein-processing suite.
Fri Aug 08, 2014
Dr. Jeff Hersh: What causes monoarticular arthritis?
Q: My left knee started to swell up and hurt, and my doctor said it was some kind of arthritis and he gave me an antibiotic.